CareDx Director Dr. Amy Abernethy Resigns Board Seat to Become Principal Deputy Commissioner of the FDA
"On behalf of our management team and Board of Directors, I would like to thank Amy for her thoughtful contributions, commitment and leadership on our Board," commented
"It has been a pleasure to serve on CareDx’s Board of Directors,” said Dr. Abernethy. “Within the last year we have seen tremendous positive impact on patients, the organization and in value creation, as the team executed well against their transplant-focused genomic information strategy.
Dr. Abernethy has served as a director on the Company's Board of Directors since
For more information, please visit: www.CareDx.com.
Integrated Corporate Relations, Inc.
Source: CareDx, Inc.